Clinical Trials Logo

Clinical Trial Summary

Objectives: To examine whether dynamic Optical Coherence Tomography (OCT) could characterize vessel dimensions and blood flow of telangiectasias before and after treatment with Intense Pulsed Light (IPL).

Methods: Dynamic-OCT (D-OCT) imaged telangiectasia characterized blood vessel width and depth, blood flow, and attenuation. Measurements were done immediately before and after, 1-3 days after, and 1 month after IPL treatment. Characterization of vessel dimensions at baseline were verified by a blinded observer. At one-month follow-up, clinical improvement was characterized as good, moderate or none and possible adverse effects were described.


Clinical Trial Description

Introduction Telangiectasia of the face are a common facial cosmetic disorder and may cause severe psychological distress. Facial telangiectasia may be treated with pulsed dye laser (PDL) or intense pulsed light (IPL). Clinical results are not always satisfactory and numerous treatments may be necessary to achieve acceptable results. Unexperienced operators often depend on treatment guidelines provided by the manufacturer when selecting energy settings for treatment, while more experienced operators may be guided by the immediate post-treatment biological endpoints and history of adverse events from previous treatment sessions. Thus, several treatments are often needed to determine optimal energy settings for the individual patient.

In general, light energy must be targeted to individual blood vessel dimensions, when optimizing laser or IPL treatment of vascular lesions. In clinical practice it may however be challenging to decide vessel width, vessel depth and blood flow by merely looking at the skin.

Optical coherence tomography (OCT) is a non-invasive in vivo imaging technique, which provides images of superficial skin structures. It has previously been demonstrated that OCT can visualize facial telangiectasias before and after IPL treatment. Dynamic OCT (D-OCT) adds identification and measurement of superficial cutaneous blood vessels with great certainty. Therefore, the aim of this study was to investigate whether D-OCT could be utilized to characterize vessel dimensions and blood flow of facial telangiectasias before and after IPL treatment.

Material and Methods Patients with telangiectasias visiting the Department of Dermatology for IPL treatment of telangiectasia at the Zealand University Hospital, Roskilde, between February and November 2018 were offered participation after informed consent. The study was approved by the Science Ethics Committee of Region Zealand (Approval no.: SJ-651) and the Danish Data Protection Agency (Approval no.: REG-177-2017).

D-OCT imaging was done immediately before, 1-3 days after, and one month after scheduled IPL treatment. The D-OCT scans and IPL treatments were performed by two separate physicians and the treating physician was blinded to all information obtained by D-OCT.

The IPL treatments were performed using a Palomar ICONTM Laser and Intense Pulsed Light platform applying a MaxGTM Optimized Handpiece with a dual-band wavelength of 500-670 nm and 870-1200 nm.

Dynamic OCT scans were performed by the 1305 nm VivoSight DX (Michelson Diagnostics, Kent, UK) with penetration depth of approximately 1 mm and vertical/horizontal optical resolution of less than 5/7.5 µm, respectively.

Drawn templates of appropriate facial telangiectasia ensured consistency of consecutive scans. Measurements of vessel dimensions were performed at the most evident level at horizontal images and verified by a blinded observer (PLA). A blinded (PLA) as well as an un-blinded evaluator (EHT) characterized vascular morphology at horizontal images from baseline and one-month follow-up. Clinical observations at one-month follow-up included changes in facial telangiectasia and registration of any adverse effects. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04274842
Study type Interventional
Source Zealand University Hospital
Contact
Status Completed
Phase N/A
Start date February 1, 2018
Completion date October 1, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Completed NCT00378196 - Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial Phase 1
Terminated NCT04336163 - Skin Imaging to Inform Laser Treatments N/A
Completed NCT02286804 - Ultherapy for the Treatment of Spider Veins on the Legs N/A
Completed NCT03472859 - Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser N/A
Completed NCT01491620 - Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte N/A
Recruiting NCT06259292 - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Completed NCT04148950 - Effects of Kinesio Taping Method on Functional Capacity and Quality of Life in Patients With Chronic Venous Disease N/A
Completed NCT00457067 - Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation Phase 1
Completed NCT00457145 - Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation Phase 1
Completed NCT04795310 - Clinical Observation of Pulsed Dye Laser and Intense Pulsed Light in Treating Facial Telangiectasia N/A
Recruiting NCT05978986 - Efficiency of Determining the Clinical Class of Chronic Venous Disorders by Artificial Intelligence N/A
Completed NCT05036200 - Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma N/A